[8.5 year-follow-up of combined heart-lung transplantation in a patient]

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Feb;38(2):212-5. doi: 10.3969/j.issn.1672-7347.2013.02.018.
[Article in Chinese]

Abstract

To summarize the case of combined heart-lung transplantation for a patient who survived for 8.5 years. On September 20, 2003, at Second Xiangya Hospital of Central South University, homologous heartlung transplantation was performed on a male patient who was diagnosed with cardiopulmonary failure secondary to congenital ventricular septal defect with severe pulmonary hypertension. Heart-lung allograft was preserved with 1500 mL modified St.Thomas solution and 3000 mL modified LPD solution. Postoperative immunosuppressive therapies included: methylprednisolone and human anti-lymphocyte globulin protein in the induction period; and combination of ciclosporin A, CellCept and prednisolone in the stable period. In 2007, the treatment was changed to CellCept mg, twice a day+FK506 4 mg, twice a day. The patient lived 8.5 years of normal life with cardiac function of NYHA I-II. Echocardiogram showed left ventricular ejection fraction of 61% to 74%. Heart-lung transplantation proved reliable therapy modality for terminal cardiopulmonary failure. Excellent donor organ preservation and proper perioperative treatment are key factors for long-term survival after heart-lung transplantation.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Eisenmenger Complex / surgery
  • Follow-Up Studies
  • Graft Rejection
  • Heart Septal Defects, Ventricular / complications
  • Heart Septal Defects, Ventricular / surgery*
  • Heart-Lung Transplantation / methods*
  • Humans
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / surgery*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Young Adult

Substances

  • Immunosuppressive Agents